SCHEMBL4011476

SCHEMBL4011476

O=C(Nc1n[nH]c2ccc(S(=O)(=O)Nc3ccc(Cl)c(Cl)c3)cc12)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ AAK1 Q2M2I8 1/20 0.49
▸ CDK7 P50613 8/20 0.48
▸ JAK2 O60674 2/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ MAP2K4 P45985 1/20 0.47
▸ FGFR1 P11362 2/20 0.47
▸ FGFR3 P22607 2/20 0.47
▸ FGFR2 P21802 1/20 0.47
▸ ULK1 O75385 1/20 0.47
▸ TP53 P04637 1/20 0.45
▸ LRRK2 Q5S007 1/20 0.45
▸ CDC7 O00311 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ CHEK1 O14757 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ DCLK1 O15075 1/20 0.45
▸ MAPK13 O15264 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010147 0.96 JAK2 (0.50) HDAC6RAB9ANPC1AAK1CDK7
SCHEMBL4007934 0.84 MAPT (0.61) RAB9ANPC1AAK1CDK7JAK2
SCHEMBL4003366 0.83 GPR27 (0.55) MAP2K4TP53MAP4K4CDK1MARK3
SCHEMBL1460604 0.82 MAPT (0.58) AAK1CDK7JAK2JAK1MAP2K4
SCHEMBL1461738 0.82 JAK2 (0.52) AAK1CDK7JAK2JAK1FGFR1
SCHEMBL4008460 0.82 CDK7 (0.48) HDAC6CDK7JAK2FGFR1FGFR3
SCHEMBL4009760 0.80 MAP2K4 (0.63) MAP2K4TP53AURKAAURKB
SCHEMBL4003421 0.80 CDK7 (0.48) HDAC6CDK7JAK2FGFR1FGFR3
SCHEMBL4008121 0.79 GPR27 (0.55) JAK2JAK1TP53AURKAMAP4K4
SCHEMBL16934639 0.79 CDK7 (0.57) HDAC6CDK7JAK2JAK1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 — — CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 — — CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HDAC6 562/4885RAB9A 2902/4885NPC1 3050/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 HDAC6 610/4885RAB9A 2870/4885NPC1 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback